Key Leaders’ Opinion on Urogenital Cancer: Frontier and Progress

Posted On 2019-03-25 09:54:07
Key Leaders’ Opinion on Urogenital Cancer: Frontier and Progress
Editors: Xinghuan Wang, Guillaume Ploussard, Emmanuel S. Antonarakis

Publisher: AME Publishing Company; 1st edition (2019)
ISBN-13: 978-988-79496-0-2
Hardcover: 183 pages
Language: English
Available at:
The book is divided into seven sections: progress in cancer genomics, molecular biology and pathology of cancer, metabolism and malignant properties, urine and exosomes, precision medicine in cancer, targeting cancer and molecular evaluation of cancer prognosis. Each section gives a comprehensive and insightful review on urogenital cancers, such as prostate cancer, bladder cancer, renal cell carcinoma, etc. It is an exciting time of translation from bench to bedside in cancer personalized medicine and molecular pathology have the potential to be the guiding hand in determining optimal treatment regimen of targeted therapies for patients with advanced diseases. Through this book, we intended to cover the recent developments in urogenital cancers at the research and at the clinical trial fronts bringing our readers' up to speed. We hope that the material and overview of the current state of research covered in this book will provide sufficient intellectual stimulations for our readers to venture new ideas into their research and clinical practices.


Felix K. H. Chun Department of Urology, University Hospital Frankfurt a.M., Germany
Jyotsna Batra School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Australian Prostate Cancer Research Centre- Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Brisbane, Australia


Xinghuan Wang Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China; Center for Evidence-Based and Translational Medicine of Wuhan University, Wuhan, China
Guillaume Ploussard Department of Urology, Saint Jean Languedoc Hospital, Toulouse, France; Division of Uro-Oncology, Institut Universitaire du Cancer Toulouse, Toulouse, France
Emmanuel S. Antonarakis Departments of Oncology and Urology, Johns Hopkins University, USA


Peng Zhang Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
Matteo Santoni Oncology Unit, Macerata Hospital, Macerata, Italy
Gopal N. Gupta Department of Urology, Loyola University Medical Center, Maywood, IL, USA

Click the book to view the entire PDF